Immunean Israeli biotech, has ventured onto the international stage with its integrated development environment (IDE) focused on immune system mapping. Based in New York, the start-up recently signed a major contract with AstraZenecaworth $18 millionaimed at optimizing clinical trials of cancer drugs.

Immunai: Innovation in the service of health

Founded in 2018 by Noam Solomon and Luis Voloch, both Harvard and MIT alumni, Immunai specializes in mapping and reprogramming the immune system. It focuses on the development of immunomodulatory therapies based on:

• Single cell genomics
• Machine learning

These technologies enable in-depth understanding of the genetic composition of individual cells. With significant experience in machine learning, Immunai’s founders bring valuable expertise to biotech.

Improve clinical decision making

The partnership with AstraZeneca aims to improve the clinical decision makingparticularly with regard to:

• Dose selection
• Identification of biomarkers

According to Iker Huerga, data scientist for oncology R&D at AstraZeneca, this collaboration will provide a better understanding of the mechanisms of action of immunotherapies. Immunai offers an innovative solution to overcome current challenges in the pharmaceutical industry.

Challenges to be met in the pharmaceutical industry

The health sector faces several challenges, one being the lack of robust biomarkers which complicates:

• Prediction of treatment response
• Patient stratification

In addition, the development of new drugs is recognized to be expensive And longoften exceeding a billion dollars. By collaborating with start-ups like Immunai, AstraZeneca hopes to reduce both the cost and time associated with research and development.

AstraZeneca: Innovator in technological investment

AstraZeneca is not just getting started on this path. Last year, the company signed a contract with Absci to design an anti-cancer antibody, a project of $247 million. This agreement includes R&D funding, milestone payments, and sales royalties.

In addition, the firm recently acquired Amolyt Pharma for an amount of up to $1.05 billionillustrating its commitment to investing in innovative solutions in the healthcare field.

Artificial Intelligence: A springboard for health

The healthcare sector is evolving rapidly with the adoption of artificial intelligence (AI), both in France and across Europe. The Covid-19 pandemic has reinforced this trend, highlighting the importance of integrating modern technologies to improve healthcare.

To support this digital evolution, the European Union has initiated the creation of a European Health Data Area. This project aims to:

• Facilitate citizens’ access to their health data
• Accelerate the secondary use of this data

These efforts also aim to harmonize essential rights, such as the right to access and object to the processing of health data.

Conclusion

Immunai and AstraZeneca are leading the way in a new era in cancer treatment through innovation and technology. Their collaboration highlights the importance of artificial intelligence and genomics in healthcare, and lays the foundation for more efficient and targeted research. The future of oncology looks promising thanks to these revolutionary advances.